Literature DB >> 10065510

[CA19-9 has no value as a tumor marker in obstructive jaundice].

R Peterli1, B Meyer-Wyss, U Herzog, P Tondelli.   

Abstract

In the differential diagnosis of pancreatic cancer, CA19-9 appears to be the most sensitive and specific marker currently in use. In the absence of jaundice and at levels greater than 1000 U/ml, the specificity is almost 100%. Levels higher than 1000 U/ml are very uncommon for benign diseases. We report a case of obstructive jaundice due to an impacted stone in the common bile duct with cholangitis, where a CA19-9 level of 61,800 U/ml prompted suspicion of a malignant cause. After treatment the CA19-9 returned to a normal level. One year postoperatively neither abdominal ultrasound nor CT-scan showed any sign of intraabdominal malignancy. Reviewing the literature, we conclude that even very high levels of CA19-9 in cases with obstructive jaundice can be caused by benign diseases. Unlike other tumour markers (alpha-foetoprotein, carcinoembryonic antigen), where exceedingly high levels are definitely caused by malignancy, high levels of CA19-9 can be caused by benign obstructive jaundice. In such cases CA19-9 is useless as a tumour marker. The biliary obstruction must be treated successfully and more diagnostic procedures or even laparotomy performed, to exclude malignancy or treat a benign disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065510

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  7 in total

1.  [CA 19-9 in the differential diagnosis of pancreatic lesions].

Authors:  S Stintzing; C Herold; E G Hahn; F Boxberger
Journal:  Internist (Berl)       Date:  2008-02       Impact factor: 0.743

2.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

3.  Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.

Authors:  Matthew A Firpo; David Z Gay; Steven R Granger; Courtney L Scaife; James A DiSario; Kenneth M Boucher; Sean J Mulvihill
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

Review 4.  Extrapulmonary sarcoidosis of liver and pancreas: a case report and review of literature.

Authors:  Hermann Harder; Markus W Büchler; Boris Fröhlich; Philipp Ströbel; Frank Bergmann; Wolfgang Neff; Manfred V Singer
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

5.  Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.

Authors:  Kyong Joo Lee; Seung Woo Yi; Moon Jae Chung; Seung Woo Park; Si Young Song; Jae Bock Chung; Jeong Youp Park
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

6.  Mirrizi Syndrome and Markedly Elevated Levels of Carbohydrate Antigen 19-9 in the Absence of Malignant Disease.

Authors:  Natasha Shah; Eula Tetangco; Hafiz Muhammad Sharjeel Arshad; Hareth Raddawi
Journal:  Case Rep Gastrointest Med       Date:  2017-04-26

7.  Biochemical profile of bile fluid in patients with malignant cholestasis in comparison with cholestasis due to gall stone.

Authors:  Hassan Taheri; Naser Ghemian; Yaser Taghavi; Javad Shokry-Shirani
Journal:  Caspian J Intern Med       Date:  2015
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.